Last reviewed · How we verify
AbobotulinumtoxinA dose level 1 or 2
AbobotulinumtoxinA dose level 1 or 2 is a Botulinum toxin Biologic drug developed by Galderma R&D. It is currently in Phase 2 development for Glabellar lines, Frown lines, Cervical dystonia.
AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscle contractions.
AbobotulinumtoxinA is a botulinum toxin type A that works by temporarily paralyzing muscle contractions. Used for Glabellar lines, Frown lines, Cervical dystonia.
At a glance
| Generic name | AbobotulinumtoxinA dose level 1 or 2 |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Botulinum toxin |
| Target | Acetylcholine release |
| Modality | Biologic |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It does this by blocking the release of acetylcholine, a neurotransmitter that signals muscle contractions. This results in a reduction in muscle spasms and contractions. AbobotulinumtoxinA is used to treat a variety of conditions, including facial wrinkles and muscle spasms.
Approved indications
- Glabellar lines
- Frown lines
- Cervical dystonia
- Axillary hyperhidrosis
Common side effects
- Eyelid ptosis
- Diplopia
- Headache
- Injection site pain
- Nausea
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. (PHASE1, PHASE2)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses (PHASE3)
- Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection (NA)
- A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants (PHASE3)
- Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach (NA)
- Botox or Botox With Esophageal Dilation in Patients With Achalasia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AbobotulinumtoxinA dose level 1 or 2 CI brief — competitive landscape report
- AbobotulinumtoxinA dose level 1 or 2 updates RSS · CI watch RSS
- Galderma R&D portfolio CI
Frequently asked questions about AbobotulinumtoxinA dose level 1 or 2
What is AbobotulinumtoxinA dose level 1 or 2?
How does AbobotulinumtoxinA dose level 1 or 2 work?
What is AbobotulinumtoxinA dose level 1 or 2 used for?
Who makes AbobotulinumtoxinA dose level 1 or 2?
What drug class is AbobotulinumtoxinA dose level 1 or 2 in?
What development phase is AbobotulinumtoxinA dose level 1 or 2 in?
What are the side effects of AbobotulinumtoxinA dose level 1 or 2?
What does AbobotulinumtoxinA dose level 1 or 2 target?
Related
- Drug class: All Botulinum toxin drugs
- Target: All drugs targeting Acetylcholine release
- Manufacturer: Galderma R&D — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Glabellar lines
- Indication: Drugs for Frown lines
- Indication: Drugs for Cervical dystonia
- Compare: AbobotulinumtoxinA dose level 1 or 2 vs similar drugs
- Pricing: AbobotulinumtoxinA dose level 1 or 2 cost, discount & access